Fenix Innovation Group
Quick facts
Phase 3 pipeline
- NTI164 · Diabetes
NTI164 is a small molecule that acts as a selective inhibitor of the SGLT2 transporter.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: